On the other hand, KRAS and TP53 co-mutation increase response rate and survival to first-line pembrolizumab in NSCLC with PD-L1 ≥ 50% compared to wild-type KRAS patients [46]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.